Endocrine treatment of prostate cancer - Recent developments and the future. Part 1: Maximal androgen blockade, early vs delayed endocrine treatment and side-effects

BJU International

Volumn 83, Issue 2, 1999, Pages 161-170

  Schroder F H ^a  

^a ERASMUS MEDICAL CENTER   (Netherlands)

Author keywords

[No Author keywords available]

Indexed keywords

ANTIANDROGEN; CYPROTERONE ACETATE; FLUTAMIDE; NILUTAMIDE;

AGED; ANEMIA; CANCER GROWTH; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DIARRHEA; HORMONAL THERAPY; HUMAN; MAJOR CLINICAL STUDY; MALE; MALE SEXUAL DYSFUNCTION; META ANALYSIS; ORCHIECTOMY; OSTEOPOROSIS; PHASE 2 CLINICAL TRIAL; PRIORITY JOURNAL; PROSTATE CANCER; RANDOMIZED CONTROLLED TRIAL; REVIEW;

ANDROGEN ANTAGONISTS; ANTINEOPLASTIC AGENTS; FORECASTING; HUMANS; IMPOTENCE; LIBIDO; MALE; META-ANALYSIS; ORCHIECTOMY; PROSTATIC NEOPLASMS; RANDOMIZED CONTROLLED TRIALS;

EID: 0033058189     PISSN: 14644096     EISSN: None     Source Type: Journal    
DOI: 10.1046/j.1464-410X.1999.00955.x     Document Type: Review

References (37)

1. 1 Schröder FH. Endocrine treatment of prostate cancer. In Walsh PC, Retik AB, Vaughan ED, Wein AJ, eds. Campbell's Urology. Chap 89. Philadelphia: WB Saunders Co., 1997: 2627-44
2. 2 Robinson MRG, Smith PH, Richards B, Newling DWW, de Pauw M, Sylvester R. The final analysis of the EORTC Genito-Urinary Group Phase III clinical trial (Protocol 30805) comparing orchidectomy, orchidectomy plus cyproterone acetate and low dose stilboestrol in the management of metastatic carcinoma of the prostate. Eur Urol 1995; 28: 273-83
3. 3 Labrie F, Dupont A, Belanger A et al. New approaches in the treatment of prostate cancer: complete instead of partial withdrawal of androgens. The Prostate 1983; 4: 579-94
4. 4 Crawford ED, Eisenberger MA, McLeod Spaulding JT et al. A controlled trial of Leuprolide with and without Flutamide in prostatic carcinoma. New Eng J Med 1989; 321: 419-24
5. 5 Denis LJ, Carneiro de Moura JL, Bono A et al. Goserelin acetate and flutamide versus bilateral orchiectomy: a phase III EORTC trial (30853). Urology 1993; 42: 119-30
6. 6 LeLorier J, Grégoire G, Benhaddad A, Lapierre J, Derderian F. Discrepancies between meta-analyses and subsequent large randomized, controlled trials. New Engl J Med 1997; 337: 536-42
7. 7 Prostate Cancer Trialists' Collaborative Group (PCTCG). Maximum androgen blockade in advanced prostate cancer: an overview of 22 randomised trials with 3283 deaths in 5710 patients. Lancet 1995; 346: 265-9
8. 8 Prostate Cancer Trialists' Collaborative Group (PCTCG). Maximum androgen blockade in advanced prostate cancer: a metaanalysis of 22 randomised trials. Eur Urol Update Series 1995; 4: 186-94
9. 9 Eisenberger MA, Blumenstein BA, Crawford ED et al. Bilateral orchiectomy with or without flutamide for metastatic prostate cancer. N Engl J Med 1998; 339: 1036-42
10. 10 The Medical Research Council Prostate Cancer Working Party Investigators Group. Immediate versus deferred treatment for advanced prostatic cancer: initial results of the Medical Research Council Trial. Br J Urol 1997; 79: 235-46
11. 11 de Voogt HJ, Studer U, Schröder FH et al. Final analysis of EORTC GU group trial 30843. Eur Urol 1998; 33: 152-8
12. 12 van den Ouden D, Tribukait B, Blom JHM et al. Deoxyribonucleic acid ploidy of core biopsies and metastatic lymph nodes of prostate cancer patients: impact on time to progression. J Urol 1993; 150: 400-6
13. 13 Byar DP, Corle DK. Hormone therapy for prostate cancer: results of the Veterans Administration Cooperative Urological Research Group Studies. NCI Monograph 1988; 7: 165-70
14. 14 Adolfsson J. Deferred treatment of low grade stage T3 prostate cancer without distant metastases. J Urol 1993; 149: 326-9
15. 15 Pound CR, Partin AW, Walsh PC. The natural history of progression to metastases and death due to prostate cancer in men with PSA recurrence following radical prostatectomy. J Urol (Suppl) 1998; 159: 334, A1283
16. 16 van den Ouden D, Hop WCJ, Kranse R, Schröder FH. Tumour control according to pathological variables in patients treated by radical prostatectomy for clinically localized carcinoma of the prostate. Br J Urol 1997; 79: 203-11
17. 17 Johansson JE, Holmberg L, Johansson S, Bergström R, Adami HO. Fifteen-year survival in prostate cancer. A prospective, population-based study in Sweden. JAMA 1997; 277: 467-71
18. 18 Adolfsson J, Steineck G, Hedlund P-O. Deferred treatment of clinically localized low-grade prostate cancer: actual 10-year and projected 15-year follow-up of the Karolinska series. Urology 1997; 50: 722-6
19. 19 Lowe BA, Liström MB. Incidental carcinoma of the prostate: an analysis of the predictors of progression. J Urol 1988; 140: 1340-4
20. 20 Epstein JI, Paull G, Eggleston JC, Walsh PC. Prognosis of untreated stage A1 prostatic carcinoma: a study of 94 cases with extended follow-up. J Urol 1986; 136: 837-9
21. 21 Blute ML, Zincke H, Farrow GM. Long-term follow-up of young patients with stage A adenocarcinoma of the prostate. J Urol 1986; 136: 840-3
22. 22 Stenman UH, Hakama M, Knekt P, Aromaa A, Teppo L, Leinonen J. Serum concentrations of prostate-specific antigen and its complex with α1-antichymotrypsin before diagnosis of prostate cancer. Lancet 1994; 334: 1594-8
23. 23 Smart ChR. Prostate cancer facts and fiction. Guest Editorial. J Surg Oncol 1997; 66: 223-9
24. 24 Newcomer LM, Stanford JL, Blumenstein BA, Brawer MK. Temporal trends in rates of prostate cancer: declining incidence of advanced stage disease. 1974-94. J Urol 1997; 158: 1427-30
25. 25 Rietbergen J, Hoedemaeker RF. The changing pattern of prostate cancer at diagnosis. In Proceedings ESU Organized Symposium on 'Prostate Cancer - Epidemiology, Prevention and Endocrine Treatment', Budapest, Hungary, October 1997. New York, London: Parthenon Publishing Group. 1998: 10-2
26. 26 Blackard CE, Byar DP, Jordan WP. Orchiectomy for advanced prostatic carcinoma. Urology 1973; 1: 553-60
27. 27 Andriole G, Lieber M, Smith J et al. Treatment with Finasteride following radical prostatectomy for prostate cancer. Urology 1995; 45: 491-7
28. 28 Ellis WJ, Grayhack JT. Sexual function in aging males after orchiectomy and estrogen therapy. J Urol 1963; 89: 895-9
29. 29 Schröder FH, and members of the EORTC Genitourinary Group. Prostate cancer treated by antiandrogens - is preservation of sexual function possible? 1998; in press
30. 30 Daniell HW. Osteoporosis after orchiectomy for prostate cancer. J Urol 1997; 157: 439-44
31. 31 Eriksson S, Eriksson A, Stege R, Carlström K. Bone mineral density in patients with prostatic cancer treated with orchidectomy and with estrogens. Calcif Tissue Int 1995; 57: 97-9
32. 32 McGrath SA, Diamond T. Osteoporosis as a complication of orchiectomy in 2 elderly men with prostatic cancer. J Urol 1995; 154: 535-6
33. 33 Strum SB, McDermed JE, Scholz MC. Johnson H, Tisman G. Anaemia associated with androgen deprivation in patients with prostate cancer receiving combined hormone blockade. Br J Urol 1997; 79: 933-41
34. 34 Weber JP, Walsh PC, Peters CA. Spivak JL. Effect of reversible androgen deprivation on hemoglobin and serum immunoreactive erythropoietin in men. Am J Hematol 1991; 36: 190-4
35. 35 Warner CL, Griffin JE, Wilson JD et al. X-linked spinomuscular atrophy: a kindred with associated abnormal androgen receptor binding. Neurology 1992; 42: 2181-4
36. 36 Morley JE, Kaiser FE, Hajjar R, Perr HM III. Testosterone and frailty. Clin Geriat Med 1997; 13: 685-95
37. 37 Goldenberg SL, Bruchovsky N, Gleave ME, Sullivan LD, Akakura K. Intermittent androgen suppression in the treatment of prostate cancer: a preliminary report. Urology 1995; 45: 839-45